Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis (Q38795815)

From Wikidata

Revision as of 06:36, 9 December 2022 by KrBot (talk | contribs) (‎Set a claim value: title (P1476): Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 10 November 2016

Language	Label	Description	Also known as
English	Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis	scientific article published on 10 November 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

0 references

1 reference

based on heuristic

inferred from title

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

Leire Aguinagalde

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mirian Domenech

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

María Luisa Antequera Gómez

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Bruno Corsini

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Susana Ruiz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Asunción Fenoll

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ernesto García

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Pedro García

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

0 references

publication date

10 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

6148-6157

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Pathogenesis, treatment, and prevention of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Pathogenesis and pathophysiology of pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Effectiveness of pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Vaccine escape recombinants emerge after pneumococcal vaccination in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Emergence of Amoxicillin-Resistant Variants of Spain9V-ST156 Pneumococci Expressing Serotype 11A Correlates with Their Ability to Evade the Host Immune Response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Purification and polar localization of pneumococcal LytB, a putative endo-beta-N-acetylglucosaminidase: the chain-dispersing murein hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

LytB, a novel pneumococcal murein hydrolase essential for cell separation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Nasopharyngeal colonization and invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Structure of pneumococcal peptidoglycan hydrolase LytB reveals insights into the bacterial cell wall remodeling and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Antibodies to the iron uptake ABC transporter lipoproteins PiaA and PiuA promote opsonophagocytosis of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Available carbon source influences the resistance of Neisseria meningitidis against complement

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Pneumonia: the leading killer of children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Review: current and new generation pneumococcal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Systemic and mucosal protective immunity to pneumococcal surface protein A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Allelic variation of polymorphic locus lytB, encoding a choline-binding protein, from streptococci of the mitis group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Of mice and not men: differences between mouse and human immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Human neutrophils kill Streptococcus pneumoniae via serine proteases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Septicemia in granulocytopenic patients: a shift in bacterial etiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Increased chain length promotes pneumococcal adherence and colonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccina

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.001

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2016.11.001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27840016%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38795815&oldid=1786984465"